Stock comparison
Bausch Health Companies
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BHC
Bausch Health Companies
Market cap
$2.04B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BHC | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 50C | 65C | GMAB |
| Benjamin Graham | 18F | 64C | GMAB |
| Philip Fisher | 47D | 48D | GMAB |
| Peter Lynch | 17F | 25F | GMAB |
| Joel Greenblatt | 17F | 76B | GMAB |
| Charlie Munger | 56D | 68C | GMAB |
| Terry Smith | 49D | 71C | GMAB |
Side-by-side metrics
| Metric | BHC | GMAB |
|---|---|---|
| Market cap | $2.04B | $16.5B |
| P/E (TTM) | - | 6.2x |
| EV/EBIT | 9.7x | 12.0x |
| ROIC (TTM) | 11.59% | 43.78% |
| Gross margin | 61.67% | 93.88% |
| Net margin | -11.27% | 18.23% |
| Revenue CAGR 5y | 5.49% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | - | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BHC leads on
- Revenue CAGR 5y5.49%vs -18.45%+130%
- P/E (TTM)-vs 6.2x+127%
- Debt / Equity-vs 0.1x+101%
- EV/EBIT9.7xvs 12.0x+19%
GMAB leads on
- Net margin18.23%vs -11.27%+162%
- Market cap$16.5Bvs $2.04B+88%
- ROIC (TTM)43.78%vs 11.59%+74%
- Gross margin93.88%vs 61.67%+34%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.